Hao Juan, Yuan Bi-bo, Xu Yuan-fu, Yu Juan, Liu Guo-yan, Wang De-hua
Department of Obstetrics and Gynecology, General Hospital, Tianjin Medical University, China.
Zhonghua Zhong Liu Za Zhi. 2012 Jun;34(6):419-24. doi: 10. 3760/cma.j.issn.0253-3766.2012.06.005.
To investigate the changes of drug sensitivity of spindle poison-induced polyploid tumor cells to chemotherapeutic agents and its possible mechanism.
Nocodazole in a dose of 100 ng/ml was used to induce polyploidization in a breast cancer cell line MDA-MB-231 cells. The polyploid cells (T-MDA-MB-231) were sorted by flow cytometry. The morphological changes and proliferation of T-MDA-MB-231 cells were compared with that of MDA-MB-231 cells. The cell growth inhibition was assessed by MTT assay. The cells were treated with paclitaxel, docetaxel, vincristine, epirubicin, 5-Fu, VP16 and oxaliplatin, respectively. Those cells were labeled with annexin V-FITC/PI and analyzed by flow cytometry. Bcl-2 was knocked down in T-MDA-MB-231 cells using SiRNA and their growth inhibition was evaluated by MTT assay to evaluate the reversing effect of Bcl-2-silencing on drug resistance.
The polyploid T-MDA-MB-231 cells grew in vitro continuously and maintained constant DNA content. They had a larger cell size, and grew more slowly than MDA-MB-231 cells. The IC(50(s)) of T-MDA-MB-231 cells were significantly higher than that of the MDA-MB-231 cells: paclitaxel: (6.37 ± 0.07) vs. (2.05 ± 0.83) µmol/L; docetaxel: (32.98 ± 1.48) vs. (11.95 ± 0.98) µmol/L; vincristine: (35.28 ± 1.66) vs. (14.58 ± 0.94) µmol/L; oxaliplatin: (19.07 ± 0.45) vs. (9.75 ± 1.05) µmol/L; 5-Fu: (85.49 ± 3.21) vs. (31.35 ± 1.51) µmol/L; and epirubicin: (0.53 ± 0.06) vs. (0.15 ± 0.01) µmol/L, (all P < 0.05). The IC(50(s)) of VP16 in T-MDA-MB-231 cells was (2.85 ± 0.50)µmol/L, significantly lower than the (12.20 ± 1.55) µmol/L in MDA-MB-231 cells (P < 0.05), and that of T-MDA-MB-231 cells after Bcl-2-knocked down by siRNA was (19.59 ± 0.48) µmol/L, significantly higher than the (12.20 ± 1.55) µmol/L in the MDA-MB-231 cells (P < 0.05). The IC(50(s)) of docetaxel of T-MDA-MB-231 cells after Bcl-2-knocked down by siRNA was (21.52 ± 0.68) µmol/L, significantly decreased and lower than that before Bcl-2 silencing (32.98 ± 1.48) µmol/L.
Our results indicate that polyploid tumor cells induced by spindle poison Nocodazole are more resistant to most of chemotherapeutic drugs. Downregulation of Bcl-2 increases the sensitivity of polyploid cells to docetaxel. The high expression of Bcl-2 may be one of the drug resistance mechanisms of polyploid tumor cells. The polyploid tumor cells are relatively sensitive to VP16, suggesting that VP16 might be an effective candidate drug for treatment of chemoresistant polyploid tumors.
探讨纺锤体毒物诱导的多倍体肿瘤细胞对化疗药物的敏感性变化及其可能机制。
采用100 ng/ml的诺考达唑诱导乳腺癌细胞系MDA-MB-231细胞多倍体化。通过流式细胞术分选多倍体细胞(T-MDA-MB-231)。比较T-MDA-MB-231细胞与MDA-MB-231细胞的形态变化和增殖情况。采用MTT法评估细胞生长抑制情况。分别用紫杉醇、多西他赛、长春新碱、表柔比星、5-氟尿嘧啶、依托泊苷和奥沙利铂处理细胞。用膜联蛋白V-FITC/PI标记细胞并通过流式细胞术分析。使用SiRNA敲低T-MDA-MB-231细胞中的Bcl-2,通过MTT法评估其生长抑制情况,以评估Bcl-2沉默对耐药性的逆转作用。
多倍体T-MDA-MB-231细胞在体外持续生长并保持恒定的DNA含量。它们的细胞体积较大,生长速度比MDA-MB-231细胞慢。T-MDA-MB-231细胞的IC50值显著高于MDA-MB-231细胞:紫杉醇:(6.37±0.07) 对 (2.05±0.83) μmol/L;多西他赛:(32.98±1.48) 对 (11.95±0.98) μmol/L;长春新碱:(35.28±1.66) 对 (14.58±0.94) μmol/L;奥沙利铂:(19.07±0.45) 对 (9.75±1.05) μmol/L;5-氟尿嘧啶:(85.49±3.21) 对 (31.35±1.51) μmol/L;表柔比星:(0.53±0.06) 对 (0.15±0.01) μmol/L,(均P<0.05)。T-MDA-MB-231细胞中依托泊苷的IC50值为(2.85±0.50)μmol/L,显著低于MDA-MB-231细胞中的(12.20±1.55) μmol/L(P<0.05),而用siRNA敲低Bcl-2后的T-MDA-MB-231细胞的IC50值为(19.59±0.48) μmol/L,显著高于MDA-MB-231细胞中的(12.20±1.55) μmol/L(P<0.05)。用siRNA敲低Bcl-2后的T-MDA-MB-231细胞多西他赛的IC50值为(21.52±0.68) μmol/L,显著降低且低于Bcl-2沉默前的(32.98±1.48) μmol/L。
我们的结果表明,纺锤体毒物诺考达唑诱导的多倍体肿瘤细胞对大多数化疗药物更具耐药性。Bcl-2的下调增加了多倍体细胞对多西他赛的敏感性。Bcl-2的高表达可能是多倍体肿瘤细胞的耐药机制之一。多倍体肿瘤细胞对依托泊苷相对敏感,提示依托泊苷可能是治疗化疗耐药多倍体肿瘤的有效候选药物。